Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.
Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.
Clareo Health | Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
